BAP Pharma, a UK-based specialist supplier of comparators for clinical trials, has announced the opening of its new U.S. headquarters in Landing, New Jersey.
The new headquarters is the company’s first location in the United States. BAP Pharma manages the clinical trial supply process including sourcing, delivery and customized solutions to provide seamless service to its clients, which include some of the UK’s top pharmaceutical companies. The decision to expand its operations to New Jersey was made in response to the company’s rapid growth, according to founder and Managing Director, Dr. Bashir Parkar. Pharmaceutical industry veteran Lucas Nigro will manage the US headquarters.
Parkar visited New Jersey during 2015 in search of a U.S. location. Choose New Jersey, a nonprofit economic development organization charged with business attraction and marketing the State, and its partners assisted Parkar in identifying real estate. BAP Pharma chose to lease a facility in Landing, which it has equipped with state of the art, fully enclosed temperature controlled ambient and cold room storage facilities.
“The facility and location proved a perfect fit for our company,” said Parkar. “Its proximity to a significant number of global pharmaceutical and biotechnology companies, including our current clients, made it particularly attractive. New Jersey’s excellent transportation network also enhances our ability to deliver products quickly and efficiently throughout the region and around the world.”
“We are excited to welcome BAP Pharma to the State’s thriving life sciences community,” said Michele Brown, President and CEO of Choose New Jersey. “Like New Jersey, the UK is a global leader in the life sciences. We’ve established strategic relations in this market through business trips and lead generation activities. New Jersey is ideally positioned to be the landing pad for international firms, based on its location in the heart of the Northeast, its diverse and talented labor pool, and the presence of the world’s top pharma and biotech companies.”